Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2007 (2007), Article ID 14983, 12 pages
http://dx.doi.org/10.1155/2007/14983
Review Article

Peroxisome Proliferator Activated Receptor Ligands as Regulators of Airway Inflammation and Remodelling in Chronic Lung Disease

Department of Pharmacology, University of Melbourne, Victoria 3010, Australia

Received 27 April 2007; Accepted 11 June 2007

Academic Editor: Theodore J. Standiford

Copyright © 2007 Jane Elizabeth Ward and Xiahui Tan. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Nolte, G. B. Wisely, and S. Westin et al., “Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ,” Nature, vol. 395, no. 6698, pp. 137–143, 1998. View at Publisher · View at Google Scholar · View at PubMed
  2. L. A. Moraes, L. Piqueras, and D. Bishop-Bailey, “Peroxisome proliferator-activated receptors and inflammation,” Pharmacology and Therapeutics, vol. 110, no. 3, pp. 371–385, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. E. S. Tien, D. B. Hannon, J. T. Thompson, and J. P. Vanden Heuvel, “Examination of ligand-dependent coactivator recruitment by peroxisome proliferator-activated receptor-α (PPARα),” PPAR Research, vol. 2006, Article ID 69612, 9 pages, 2006. View at Publisher · View at Google Scholar · View at PubMed
  4. J. Berger and D. E. Moller, “The mechanisms of action of PPARs,” Annual Review of Medicine, vol. 53, pp. 409–435, 2002. View at Publisher · View at Google Scholar · View at PubMed
  5. B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999. View at Publisher · View at Google Scholar
  6. D. S. Straus, G. Pascual, and M. Li et al., “15-deoxyΔ12,14-prostaglandin J2 inhibits multiple steps in the NF-κB signaling pathway,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 9, pp. 4844–4849, 2000. View at Publisher · View at Google Scholar
  7. P. Gervois, N. Vu-Dac, and R. Kleemann et al., “Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β,” Journal of Biological Chemistry, vol. 276, no. 36, pp. 33471–33477, 2001. View at Publisher · View at Google Scholar · View at PubMed
  8. S. G. Harris, R. S. Smith, and R. P. Phipps, “15-deoxy-Δ12,14-PGJ2 induces IL-8 production in human T cells by a mitogen-activated protein kinase pathway,” Journal of Immunology, vol. 168, no. 3, pp. 1372–1379, 2002.
  9. K. M. Patel, K. L. Wright, P. Whittaker, P. Chakravarty, M. L. Watson, and S. G. Ward, “Differential modulation of COX-2 expression in A549 airway epithelial cells by structurally distinct PPARγ agonists: evidence for disparate functional effects which are independent of NF-κB and PPARγ,” Cellular Signalling, vol. 17, no. 9, pp. 1098–1110, 2005. View at Publisher · View at Google Scholar · View at PubMed
  10. T. M. Willson, P. J. Brown, D. D. Sternbach, and B. R. Henke, “The PPARs: from orphan receptors to drug discovery,” Journal of Medicinal Chemistry, vol. 43, no. 4, pp. 527–550, 2000. View at Publisher · View at Google Scholar
  11. B. M. Forman, P. Tontonoz, J. Chen, R. P. Brun, B. M. Spiegelman, and R. M. Evans, “15-deoxy-Δ12,14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ,” Cell, vol. 83, no. 5, pp. 803–812, 1995. View at Publisher · View at Google Scholar
  12. L. C. Bell-Parikh, T. Ide, J. A. Lawson, P. McNamara, M. Reilly, and G. A. FitzGerald, “Biosynthesis of 15-deoxy-Δ12,14-PGJ2 and the ligation of PPARγ,” Journal of Clinical Investigation, vol. 112, no. 6, pp. 945–955, 2003. View at Publisher · View at Google Scholar · View at PubMed
  13. L. Benayoun, S. Letuve, and A. Druilhe et al., “Regulation of peroxisome proliferator-activated receptor γ expression in human asthmatic airways: relationship with proliferation, apoptosis, and airway remodeling,” American Journal of Respiratory and Critical Care Medicine, vol. 164, no. 8, part 1, pp. 1487–1494, 2001.
  14. C. Faveeuw, S. Fougeray, and V. Angeli et al., “Peroxisome proliferator-activated receptor γ activators inhibit interleukin-12 production in murine dendritic cells,” FEBS Letters, vol. 486, no. 3, pp. 261–266, 2000. View at Publisher · View at Google Scholar
  15. J. M. Lehmann, L. B. Moore, T. A. Smith-Oliver, W. O. Wilkison, T. M. Willson, and S. A. Kliewer, “An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ),” Journal of Biological Chemistry, vol. 270, no. 22, pp. 12953–12956, 1995. View at Publisher · View at Google Scholar
  16. G. Chinetti, S. Griglio, and M. Antonucci et al., “Activation of proliferator-activated receptors α and γ induces apoptosis of human monocyte-derived macrophages,” Journal of Biological Chemistry, vol. 273, no. 40, pp. 25573–25580, 1998. View at Publisher · View at Google Scholar
  17. M. Ricote, J. Huang, and L. Fajas et al., “Expression of the peroxisome proliferator-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 13, pp. 7614–7619, 1998. View at Publisher · View at Google Scholar
  18. T. J. Standiford, V. G. Keshamouni, and R. C. Reddy, “Peroxisome proliferator-activated receptor-γ as a regulator of lung inflammation and repair,” Proceedings of the American Thoracic Society, vol. 2, no. 3, pp. 226–231, 2005. View at Publisher · View at Google Scholar · View at PubMed
  19. G. Woerly, K. Honda, and M. Loyens et al., “Peroxisome proliferator-activated receptors α and γ down-regulate allergic inflammation and eosinophil activation,” Journal of Experimental Medicine, vol. 198, no. 3, pp. 411–421, 2003. View at Publisher · View at Google Scholar · View at PubMed
  20. S. Ueki, T. Adachi, and J. Bourdeaux et al., “Expression of PPARγ in eosinophils and its functional role in survival and chemotaxis,” Immunology Letters, vol. 86, no. 2, pp. 183–189, 2003. View at Publisher · View at Google Scholar
  21. M. E. Greene, B. Blumberg, and O. W. McBride et al., “Isolation of the human peroxisome proliferator activated receptor γ cDNA: expression in hematopoietic cells and chromosomal mapping,” Gene Expression, vol. 4, no. 4-5, pp. 281–299, 1995.
  22. V. Reynders, S. Loitsch, C. Steinhauer, T. Wagner, D. Steinhilber, and J. Bargon, “Peroxisome proliferator-activated receptor α (PPARα) down-regulation in cystic fibrosis lymphocytes,” Respiratory Research, vol. 7, p. 104, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. P. Gosset, A.-S. Charbonnier, and P. Delerive et al., “Peroxisome proliferator-activated receptor γ activators affect the maturation of human monocyte-derived dendritic cells,” European Journal of Immunology, vol. 31, no. 10, pp. 2857–2865, 2001. View at Publisher · View at Google Scholar
  24. R. B. Clark, D. Bishop-Bailey, T. Estrada-Hernandez, T. Hla, L. Puddington, and S. J. Padula, “The nuclear receptor PPARγ and immunoregulation: PPARγ mediates inhibition of helper T cell responses,” Journal of Immunology, vol. 164, no. 3, pp. 1364–1371, 2000.
  25. D. C. Jones, X. Ding, and R. A. Daynes, “Nuclear receptor peroxisome proliferator-activated receptor α (PPARα) is expressed in resting murine lymphocytes. The PPARα in T and B lymphocytes is both transactivation and transrepression competent,” Journal of Biological Chemistry, vol. 277, no. 9, pp. 6838–6845, 2002. View at Publisher · View at Google Scholar · View at PubMed
  26. H. Sugiyama, T. Nonaka, T. Kishimoto, K. Komoriya, K. Tsuji, and T. Nakahata, “Peroxisome proliferator-activated receptors are expressed in human cultured mast cells: a possible role of these receptors in negative regulation of mast cell activation,” European Journal of Immunology, vol. 30, no. 12, pp. 3363–3370, 2000. View at Publisher · View at Google Scholar
  27. A. C. C. Wang, X. Dai, B. Luu, and D. J. Conrad, “Peroxisome proliferator-activated receptor-γ regulates airway epithelial cell activation,” American Journal of Respiratory Cell and Molecular Biology, vol. 24, no. 6, pp. 688–693, 2001.
  28. A. Trifilieff, A. Bench, M. Hanley, D. Bayley, E. Campbell, and P. Whittaker, “PPAR-α and -γ but not -δ agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-κB-independent effect,” British Journal of Pharmacology, vol. 139, no. 1, pp. 163–171, 2003. View at Publisher · View at Google Scholar · View at PubMed
  29. R. Arnold and W. König, “Peroxisome-proliferator-activated receptor-γ agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells,” Virology, vol. 346, no. 2, pp. 427–439, 2006. View at Publisher · View at Google Scholar · View at PubMed
  30. M. Hetzel, D. Walcher, M. Grüb, H. Bach, V. Hombach, and N. Marx, “Inhibition of MMP-9 expression by PPARγ activators in human bronchial epithelial cells,” Thorax, vol. 58, no. 9, pp. 778–783, 2003. View at Publisher · View at Google Scholar
  31. H. A. Burgess, L. E. Daugherty, and T. H. Thatcher et al., “PPARγ agonists inhibit TGF-β induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis,” American Journal of Physiology, vol. 288, no. 6 32-6, pp. L1146–L1153, 2005. View at Publisher · View at Google Scholar · View at PubMed
  32. H. J. Patel, M. G. Belvisi, D. Bishop-Bailey, M. H. Yacoub, and J. A. Mitchell, “Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior anti-inflammatory profile to corticosteroids: relevance for chronic obstructive pulmonary disease therapy,” Journal of Immunology, vol. 170, no. 5, pp. 2663–2669, 2003.
  33. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at PubMed
  34. M. Yamashita, “Peroxisome proliferator-activated receptor α-independent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells,” European Journal of Pharmacology, vol. 556, no. 1–3, pp. 172–180, 2007. View at Publisher · View at Google Scholar · View at PubMed
  35. L. Pang, M. Nie, L. Corbett, and A. J. Knox, “Cyclooxygenase-2 expression by nonsteroidal anti-inflammatory drugs in human airway smooth muscle cells: role of peroxisome proliferator-activated receptors,” Journal of Immunology, vol. 170, no. 2, pp. 1043–1051, 2003.
  36. S. R. Kim, K. S. Lee, and H. S. Park et al., “Involvement of IL-10 in peroxisome proliferator-activated receptor γ-mediated anti-inflammatory response in asthma,” Molecular Pharmacology, vol. 68, no. 6, pp. 1568–1575, 2005. View at Publisher · View at Google Scholar · View at PubMed
  37. K. S. Lee, S. J. Park, and P. H. Hwang et al., “PPAR-γ modulates allergic inflammation through up-regulation of PTEN,” The FASEB Journal, vol. 19, no. 8, pp. 1033–1035, 2005. View at Publisher · View at Google Scholar · View at PubMed
  38. K. Honda, P. Marquillies, M. Capron, and D. Dombrowicz, “Peroxisome proliferator-activated receptor γ is expressed in airways and inhibits features of airway remodeling in a mouse asthma model,” Journal of Allergy and Clinical Immunology, vol. 113, no. 5, pp. 882–888, 2004. View at Publisher · View at Google Scholar · View at PubMed
  39. J. T. Huang, J. S. Welch, and M. Ricote et al., “Interleukin-4-dependent production of PPAR-γ ligands in macrophages by 12/15-lipoxygenase,” Nature, vol. 400, no. 6742, pp. 378–382, 1999. View at Publisher · View at Google Scholar · View at PubMed
  40. C.-J. Huang, I.-M. Liu, and J.-T. Cheng, “Increase of peroxisome proliferator-activated receptor δ gene expression in the lungs of streptozotocin-induced diabetic rats,” Pulmonary Pharmacology & Therapeutics, vol. 20, no. 1, pp. 69–74, 2007. View at Publisher · View at Google Scholar · View at PubMed
  41. I. Inoue, K. Shino, S. Noji, T. Awata, and S. Katayama, “Expression of peroxisome proliferator-activated receptor α (PPARα) in primary cultures of human vascular endothelial cells,” Biochemical and Biophysical Research Communications, vol. 246, no. 2, pp. 370–374, 1998. View at Publisher · View at Google Scholar · View at PubMed
  42. J. Becker, C. Delayre-Orthez, N. Frossard, and F. Pons, “Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases?,” Fundamental and Clinical Pharmacology, vol. 20, no. 5, pp. 429–447, 2006. View at Publisher · View at Google Scholar · View at PubMed
  43. M. Kobayashi, M. J. Thomassen, and T. Rambasek et al., “An inverse relationship between peroxisome proliferator-activated receptor γ and allergic airway inflammation in an allergen challenge model,” Annals of Allergy, Asthma & Immunology, vol. 95, no. 5, pp. 468–473, 2005.
  44. H. M. Wright, C. B. Clish, and T. Mikami et al., “A synthetic antagonist for the peroxisome proliferator-activated receptor γ inhibits adipocyte differentiation,” Journal of Biological Chemistry, vol. 275, no. 3, pp. 1873–1877, 2000. View at Publisher · View at Google Scholar
  45. L. M. Leesnitzer, D. J. Parks, and R. K. Bledsoe et al., “Functional consequences of cysteine modification in the ligand binding sites of peroxisome proliferator activated receptors by GW9662,” Biochemistry, vol. 41, no. 21, pp. 6640–6650, 2002. View at Publisher · View at Google Scholar
  46. D. Bishop-Bailey, T. Hla, and T. D. Warner, “Bisphenol A diglycidyl ether (BADGE) is a PPARγ agonist in an ECV304 cell line,” British Journal of Pharmacology, vol. 131, no. 4, pp. 651–654, 2000. View at Publisher · View at Google Scholar · View at PubMed
  47. K. S. Lee, S. R. Kim, and S. J. Park et al., “Peroxisome proliferator activated receptor-γ modulates reactive oxygen species generation and activation of nuclear factor-κB and hypoxia-inducible factor 1α in allergic airway disease of mice,” Journal of Allergy and Clinical Immunology, vol. 118, no. 1, pp. 120–127, 2006. View at Publisher · View at Google Scholar · View at PubMed
  48. T. Genovese, E. Mazzon, and R. Di Paola et al., “Role of endogenous and exogenous ligands for the peroxisome proliferator-activated receptor α in the development of bleomycin-induced lung injury,” Shock, vol. 24, no. 6, pp. 547–555, 2005. View at Publisher · View at Google Scholar
  49. P. D. G. Miles, Y. Barak, W. He, R. M. Evans, and J. M. Olefsky, “Improved insulin-sensitivity in mice heterozygous for PPAR-γ deficiency,” Journal of Clinical Investigation, vol. 105, no. 3, pp. 287–292, 2000.
  50. K. Maeyama, M. Emi, and M. Tachibana, “Nuclear receptors as targets for drug development: peroxisome proliferator-activated receptor γ in mast cells: its roles in proliferation and differentiation,” Journal of Pharmacological Sciences, vol. 97, no. 2, pp. 190–194, 2005. View at Publisher · View at Google Scholar
  51. D. M. Simon, M. C. Arikan, and S. Srisuma et al., “Epithelial cell PPARγ contributes to normal lung maturation,” The FASEB Journal, vol. 20, no. 9, pp. 1507–1509, 2006. View at Publisher · View at Google Scholar · View at PubMed
  52. M. G. Belvisi, “Regulation of inflammatory cell function by corticosteroids,” Proceedings of the American Thoracic Society, vol. 1, no. 3, pp. 207–214, 2004. View at Publisher · View at Google Scholar · View at PubMed
  53. M. Nie, L. Corbett, A. J. Knox, and L. Pang, “Differential regulation of chemokine expression by peroxisome proliferator-activated receptor γ agonists: interactions with glucocorticoids and β2-agonists,” Journal of Biological Chemistry, vol. 280, no. 4, pp. 2550–2561, 2005. View at Publisher · View at Google Scholar · View at PubMed
  54. R. Cunard, M. Ricote, and D. DiCampli et al., “Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors,” Journal of Immunology, vol. 168, no. 6, pp. 2795–2802, 2002.
  55. S. G. Harris and R. P. Phipps, “Prostaglandin D2, its metabolite 15-d-PGJ2, and peroxisome proliferator activated receptor-γ agonists induce apoptosis in transformed, but not normal, human T lineage cells,” Immunology, vol. 105, no. 1, pp. 23–34, 2002. View at Publisher · View at Google Scholar
  56. C. Mueller, V. Weaver, J. P. Vanden Heuvel, A. August, and M. T. Cantorna, “Peroxisome proliferator-activated receptor γ ligands attenuate immunological symptoms of experimental allergic asthma,” Archives of Biochemistry and Biophysics, vol. 418, no. 2, pp. 186–196, 2003. View at Publisher · View at Google Scholar
  57. Y. Fu, N. Luo, and M. F. Lopes-Virella, “Upregulation of interleukin-8 expression by prostaglandin D2 metabolite 15-deoxy-Δ12,14 prostaglandin J2 (15d-PGJ2) in human THP-1 macrophages,” Atherosclerosis, vol. 160, no. 1, pp. 11–20, 2002. View at Publisher · View at Google Scholar
  58. C. Jiang, A. T. Ting, and B. Seed, “PPAR-γ agonists inhibit production of monocyte inflammatory cytokines,” Nature, vol. 391, no. 6662, pp. 82–86, 1998. View at Publisher · View at Google Scholar · View at PubMed
  59. Y. Kobayashi, S. Ueki, and G. Mahemuti et al., “Physiological levels of 15-deoxy-Δ12,14-prostaglandin J2 prime eotaxin-induced chemotaxis on human eosinophils through peroxisome proliferator-activated receptor-γ ligation,” Journal of Immunology, vol. 175, no. 9, pp. 5744–5750, 2005.
  60. C. E. Brightling, P. Bradding, F. A. Symon, S. T. Holgate, A. J. Wardlaw, and I. D. Pavord, “Mast-cell infiltration of airway smooth muscle in asthma,” New England Journal of Medicine, vol. 346, no. 22, pp. 1699–1705, 2002. View at Publisher · View at Google Scholar · View at PubMed
  61. Y. Fujimura, H. Tachibana, and K. Yamada, “Peroxisome proliferator-activated receptor ligands negatively regulate the expression of the high-affinity IgE receptor FcεRI in human basophilic KU812 cells,” Biochemical and Biophysical Research Communications, vol. 297, no. 2, pp. 193–201, 2002. View at Publisher · View at Google Scholar
  62. K. Okuyama, M. Yamashita, Y. Kitabatake, S. Kawamura, M. Takayanagi, and I. Ohno, “Ciglitazone inhibits the antigen-induced leukotrienes production independently of PPARγ in RBL-2H3 mast cells,” European Journal of Pharmacology, vol. 521, no. 1–3, pp. 21–28, 2005. View at Publisher · View at Google Scholar · View at PubMed
  63. M. C. Liu, D. Proud, and L. M. Lichtenstein et al., “Effects of prednisone on the cellular responses and release of cytokines and mediators after segmental allergen challenge of asthmatic subjects,” Journal of Allergy and Clinical Immunology, vol. 108, no. 1, pp. 29–38, 2001. View at Publisher · View at Google Scholar · View at PubMed
  64. A. Momoi, K. Murao, and H. Imachi et al., “Thiazolidinedione inhibits production of RANTES in a cytokine-treated human lung epithelial cell line,” FEBS Letters, vol. 452, no. 3, pp. 301–304, 1999. View at Publisher · View at Google Scholar
  65. C. Desmet, B. Warzée, and P. Gosset et al., “Pro-inflammatory properties for thiazolidinediones,” Biochemical Pharmacology, vol. 69, no. 2, pp. 255–265, 2005. View at Publisher · View at Google Scholar · View at PubMed
  66. K. Subbaramaiah, D. T. Lin, J. C. Hart, and A. J. Dannenberg, “Peroxisome proliferator-activated receptor γ ligands suppress the transcriptional activation of cyclooxygenase-2. Evidence for involvement of activator protein-1 and CREB-binding protein/p300,” Journal of Biological Chemistry, vol. 276, no. 15, pp. 12440–12448, 2001. View at Publisher · View at Google Scholar · View at PubMed
  67. J. Bousquet, P. Chanez, and J. Y. Lacoste et al., “Indirect evidence of bronchial inflammation assessed by titration of inflammatory mediators in BAL fluid of patients with asthma,” Journal of Allergy and Clinical Immunology, vol. 88, no. 4, pp. 649–660, 1991. View at Publisher · View at Google Scholar
  68. M. Ebina, T. Takahashi, T. Chiba, and M. Motomiya, “Cellular hypertrophy and hyperplasia of airway smooth muscles underlying bronchial asthma. A 3-D morphometric study,” American Review of Respiratory Disease, vol. 148, no. 3, pp. 720–726, 1993.
  69. P. G. Woodruff, G. M. Dolganov, and R. E. Ferrando et al., “Hyperplasia of smooth muscle in mild to moderate asthma without changes in cell size or gene expression,” American Journal of Respiratory and Critical Care Medicine, vol. 169, no. 9, pp. 1001–1006, 2004. View at Publisher · View at Google Scholar · View at PubMed
  70. R. J. Thomson, A. M. Bramley, and R. R. Schellenberg, “Airway muscle stereology: implications for increased shortening in asthma,” American Journal of Respiratory and Critical Care Medicine, vol. 154, no. 3, part 1, pp. 749–757, 1996.
  71. J. K. Burgess, B. G. G. Oliver, and M. H. Poniris et al., “A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro,” Journal of Allergy and Clinical Immunology, vol. 118, no. 3, pp. 649–657, 2006. View at Publisher · View at Google Scholar · View at PubMed
  72. A. Ialenti, G. Grassia, P. Di Meglio, P. Maffia, M. Di Rosa, and A. Ianaro, “Mechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathway,” Molecular Pharmacology, vol. 67, no. 5, pp. 1620–1628, 2005. View at Publisher · View at Google Scholar · View at PubMed
  73. M. A. Saunders, J. A. Mitchell, and P. M. Seldon et al., “Release of granulocyte-macrophage colony stimulating factor by human cultured airway smooth muscle cells: suppression by dexamethasone,” British Journal of Pharmacology, vol. 120, no. 4, pp. 545–546, 1997.
  74. M. G. Belvisi, M. Saunders, M. Yacoub, and J. A. Mitchell, “Expression of cyclo-oxygenase-2 in human airway smooth muscle is associated with profound reductions in cell growth,” British Journal of Pharmacology, vol. 125, no. 5, pp. 1102–1108, 1998. View at Publisher · View at Google Scholar · View at PubMed
  75. J. E. Ward, H. Gould, T. Harris, J. V. Bonacci, and A. G. Stewart, “PPARγ ligands, 15-deoxy-Δ2,14-prostaglandin J2 and rosiglitazone regulate human cultured airway smooth muscle proliferation through different mechanisms,” British Journal of Pharmacology, vol. 141, no. 3, pp. 517–525, 2004. View at Publisher · View at Google Scholar · View at PubMed
  76. D. Fernandes, E. Guida, and V. Koutsoubos et al., “Glucocorticoids inhibit proliferation, cyclin D1 expression, and retinoblastoma protein phosphorylation, but not activity of the extracellular-regulated kinases in human cultured airway smooth muscle,” American Journal of Respiratory Cell and Molecular Biology, vol. 21, no. 1, pp. 77–88, 1999.
  77. P. R. A. Johnson, J. K. Burgess, and P. A. Underwood et al., “Extracellular matrix proteins modulate asthmatic airway smooth muscle cell proliferation via an autocrine mechanism,” Journal of Allergy and Clinical Immunology, vol. 113, no. 4, pp. 690–696, 2004. View at Publisher · View at Google Scholar · View at PubMed
  78. C. Delayre-Orthez, J. Becker, and I. Guenon et al., “PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse,” Respiratory Research, vol. 6, p. 91, 2005. View at Publisher · View at Google Scholar · View at PubMed
  79. J. E. Ward, D. J. Fernandes, C. C. Taylor, J. V. Bonacci, L. Quan, and A. G. Stewart, “The PPARγ ligand, rosiglitazone, reduces airways hyperresponsiveness in a murine model of allergen-induced inflammation,” Pulmonary Pharmacology & Therapeutics, vol. 19, no. 1, pp. 39–46, 2006. View at Publisher · View at Google Scholar · View at PubMed
  80. T. Genovese, S. Cuzzocrea, and R. Di Paola et al., “Effect of rosiglitazone and 15-deoxy-Δ12,14-prostaglandin J2 on bleomycin-induced lung injury,” European Respiratory Journal, vol. 25, no. 2, pp. 225–234, 2005. View at Publisher · View at Google Scholar · View at PubMed
  81. A. Trifilieff, A. El-Hashim, and C. Bertrand, “Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment,” American Journal of Physiology, vol. 279, no. 6, pp. L1120–L1128, 2000.
  82. S. Y. Lee, J. S. Kim, and J. M. Lee et al., “Inhaled corticosteroid prevents the thickening of airway smooth muscle in murine model of chronic asthma,” to appear in Pulmonary Pharmacology & Therapeutics. View at Publisher · View at Google Scholar · View at PubMed
  83. C. Ward and H. Walters, “Airway wall remodelling: the influence of corticosteroids,” Current Opinion in Allergy and Clinical Immunology, vol. 5, no. 1, pp. 43–48, 2005. View at Publisher · View at Google Scholar
  84. J. Bates, C. Irvin, and V. Brusasco et al., “The use and misuse of Penh in animal models of lung disease,” American Journal of Respiratory Cell and Molecular Biology, vol. 31, no. 3, pp. 373–374, 2004.
  85. M. A. Birrell, C. H. Battram, P. Woodman, K. McCluskie, and M. G. Belvisi, “Dissociation by steroids of eosinophilic inflammation from airway hyperresponsiveness in murine airways,” Respiratory Research, vol. 4, p. 3, 2003. View at Publisher · View at Google Scholar
  86. P. J. Henry, A. D'Aprile, G. Self, T. Hong, and T. S. Mann, “Inhibitors of prostaglandin transport and metabolism augment protease-activated receptor-2-mediated increases in prostaglandin E2 levels and smooth muscle relaxation in mouse isolated trachea,” Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 3, pp. 995–1001, 2005. View at Publisher · View at Google Scholar · View at PubMed
  87. H. Cho and H.-H. Tai, “Thiazolidinediones as a novel class of NAD+-dependent 15-hydroxyprostaglandin dehydrogenase inhibitors,” Archives of Biochemistry and Biophysics, vol. 405, no. 2, pp. 247–251, 2002. View at Publisher · View at Google Scholar
  88. H. Hammad, H. J. de Heer, and T. Soullié et al., “Activation of peroxisome proliferator-activated receptor-γ in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma,” American Journal of Pathology, vol. 164, no. 1, pp. 263–271, 2004.
  89. Y. Hashimoto and K. Nakahara, “Improvement of asthma after administration of pioglitazone,” Diabetes Care, vol. 25, no. 2, p. 401, 2002. View at Publisher · View at Google Scholar